FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesExamining Technology-Driven Trends in the Clinical Supply Chain
Topics: Pharma Industry, Technology
Position Paper
Free
2020 Virtual Conference: Presentation and Workshop Slides
Topics: Communication, Conference, Personal Development, Pharma Industry
Presentation
Members
EAP 104: EAP Communication and Stakeholder Management
Topics: Additional Concepts, Closeout, EAP, Execution, Forecasting / Planning
Presentation
Members
